Predicted broadly neutralizing antibody (bnAb) resistance and associated envelope characteristics of adults with HIV-1 seroconversion in Botswana.

Broadly neutralizing antibodies HIV-1 N-glycosylation bnAb resistance envelope characteristics in silico

Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
29 Aug 2023
Historique:
pubmed: 11 9 2023
medline: 11 9 2023
entrez: 11 9 2023
Statut: epublish

Résumé

We used HIV-1C sequences to predict (in silico) resistance to 33 known broadly neutralizing antibodies (bNAbs) and evaluate the different HIV-1 env characteristics that may affect virus neutralization. We analyzed proviral sequences from adults with documented HIV-1 seroconversion (N=140) in Botswana (2013-2018). HIV-1 env sequences were used to predict bnAb resistance using bNAb-ReP, to determine the number of potential N-linked glycosylation sites (PNGS) and evaluate env variable region characteristics (VC). We also assessed the presence of signature mutations that may affect bnAb sensitivity in vitro. We observe varied results for predicted bnAb resistance among our cohort. 3BNC117 showed high predicted resistance (72%) compared to intermediate levels of resistance to VRC01 (57%). We predict low resistance to PGDM100 and 10-1074 and no resistance to 4E10. No difference was observed in the frequency of PNGS by bNAb susceptibility patterns except for higher number of PNGs in V3 bnAb resistant strains. Associations of VC were observed for V1, V4 and V5 loop length and net charge. We also observed few mutations that have been reported to confer bnAb resistance in vitro. Our results support use of sequence data and machine learning tools to predict the best bnAbs to use within populations.

Identifiants

pubmed: 37693564
doi: 10.21203/rs.3.rs-3194948/v1
pmc: PMC10491331
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : FIC NIH HHS
ID : K43 TW012350
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : NHGRI NIH HHS
ID : U41 HG006941
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Conflict of Interest: None declared

Auteurs

Natasha Onalenna Moraka (NO)

Botswana Harvard AIDS Institute Partnership.

Wonderful T Choga (WT)

Botswana Harvard AIDS Institute Partnership.

Marea N Pema (MN)

Botswana Harvard AIDS Institute Partnership.

Moses K Chawawa (MK)

Botswana Harvard AIDS Institute Partnership.

Irene Gobe (I)

University of Botswana.

Margaret Mokomane (M)

University of Botswana.

Ontlametse T Bareng (OT)

Botswana Harvard AIDS Institute Partnership.

Lynnette Bhebhe (L)

Botswana Harvard AIDS Institute Partnership.

Nametso Kelentse (N)

Botswana Harvard AIDS Institute Partnership.

Graceful Mulenga (G)

Botswana Harvard AIDS Institute Partnership.

Molly Pretorius-Holme (M)

Harvard University.

Terence Mohammed (T)

Botswana Harvard AIDS Institute Partnership.

Catherine K Koofhethile (CK)

Botswana Harvard AIDS Institute Partnership.

Joseph M Makhema (JM)

Botswana Harvard AIDS Institute Partnership.

Roger Shapiro (R)

Harvard University.

Shahin Lockman (S)

Harvard University.

Sikhulile Moyo (S)

Botswana Harvard AIDS Institute Partnership.

Simani Gaseitsiwe (S)

Botswana Harvard AIDS Institute Partnership.

Classifications MeSH